Menlo Park, CA's 5AM Ventures has pieced together a fourth fund, roping in $250 million with its eye on a new generation of promising drug developers.
Biotech bankroller 5AM Ventures has its sights set on a $240 million fund, putting together its fourth war chest as industry venture deals continue their middling pace.
Canaan Partners and 5AM Ventures are launching a new Yale spinout focused on a new approach to shutting down proteins.
The San Francisco-based gene therapy startup Audentes Therapeutics has rounded up an impressive $30 million A round. OrbiMed Advisors led the round with 5AM Ventures and Versant Ventures joining in.
Pearl Therapeutics has grabbed a hefty $65 million venture round, enough to bankroll the launch of a key late-stage COPD drug program that--one way or another--will prove transformational for the biotech.
5AM Ventures and Canaan Partners have joined forces to lead a $23 million A round for a startup antiviral biotech based in Radnor, PA. Novira Therapeutics is developing capsid-targeting antivirals for hepatitis B and HIV.
Newly hatched Atterocor has gained the wherewithal to push ahead with a lead drug for adrenal cancer. The Ann Arbor, MI-based biotech snapped up $16 million from Frazier Healthcare and early-stage specialist 5AM Ventures, the company announced this morning.
Reston, VA-based 5AM Solutions has landed a $1.2 million contract with the Arizona Biomedical Research Commission to develop a centralized, virtual tissue bank called caTissue Suite. Available free...